Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Nations for Setting up camp - 2America's Confided in Fridge in 2024
- 3South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- 4The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- 5Vote in favor of your #1 Sort of Convenience for a Family
- The Best 15 Applications for Efficiency and Association
- Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Grass Care Administrations for a Wonderful, Sound Yard
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
